Azenta Inc (AZTA) valuation
Azenta P/E ratio history
Azenta has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 6 fiscal year ends its P/E ranged from 1.5 (year to Sep 2022) to 68.7 (year to Sep 2021), with a median of 27.7.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Sep 30, 2025 | $28.72 | -$1.23 | n/m |
| Sep 30, 2024 | $48.44 | -$2.99 | n/m |
| Sep 30, 2023 | $50.19 | -$0.22 | n/m |
| Sep 30, 2022 | $42.86 | $28.48 | 1.5 |
| Sep 30, 2021 | $102.35 | $1.49 | 68.7 |
| Sep 30, 2020 | $46.26 | $0.88 | 52.6 |
| Sep 30, 2019 | $37.03 | $6.04 | 6.1 |
| Sep 30, 2018 | $35.03 | $1.64 | 21.4 |
| Sep 30, 2017 | $30.36 | $0.89 | 34.1 |
| Sep 30, 2016 | $13.61 | -$1.01 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Azenta valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| AzentaAZTA | $1.80B | — | 82.4 | 2.9 |
| Sellas Life Sciences GroupSLS | $1.80B | — | — | — |
| Zenas BiopharmaZBIO | $1.79B | — | — | — |
| Agios PharmaceuticalsAGIO | $1.82B | — | — | 18.5 |
| Amn HealthcareAMN | $1.83B | 17.5 | 22.3 | 0.5 |
| Xeris BiopharmaXERS | $1.85B | — | 202.3 | 5.5 |
| LeMaitre VascularLMAT | $1.85B | 28.3 | 26.7 | 7.1 |
| Maze TherapeuticsMAZE | $1.74B | — | — | 87.1 |
| Intellia TherapeuticsNTLA | $1.74B | — | — | 29.3 |
| Peer median | 22.9 | 26.7 | 12.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: AZTA financials · AZTA returns
No forecast, no recommendation. This page describes Azenta Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.